



DRUG DISCOVERY

Early Stage Drug Safety Strategies and Risk Management

Maximizing opportunities towards achieving clinical success

By Dr CL Barton

Dr Cheryl L Barton

Dr Cheryl L Barton is an independent consultant with over 16 year's research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on several pan-European companies, and assessed the potential impact of new drug development on European Stocks.

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success.

Executive Summary 10

Introduction	10
Modeling and simulation in drug discovery	11
Novel <i>in vitro</i> technologies for predictive safety testing	12
Novel <i>in vivo</i> methods in for non-clinical safety assessment	12
Current initiatives in preclinical drug safety	13
Strategies to improve safety evaluation in early clinical development	14
Challenges and cost saving opportunities	16

Chapter 1 Introduction 18

Summary	18
State of the industry	19
Drug attrition	20
Innovation in drug safety	21
Report outline	28

Chapter 2 Modeling and simulation in drug discovery 32

Summary	32
Introduction	33
Molecular modeling	34
Structure-toxicity relationships	35

	Epix Pharmaceuticals' <i>in silico</i> discovery platform	37
	Cheminformatic methods	38
	Collaborative projects	41
	Biosimulation	42
	Virtual models of whole organs	43
	Conclusions	45
Chapter 3	Novel <i>in vitro</i> technologies for predictive safety testing	48
	Summary	48
	Introduction	49
	Toxicogenomics and systems biology	50
	Commercial platforms	53
	Cell-based assays	56
	Stem cells	61
	Conclusions	65
Chapter 4	Novel <i>in vivo</i> methods in for non-clinical safety assessment	68
	Summary	68
	Introduction	69
	Zebrafish	70
	Whole animal imaging and microscopy	73
	Humanized rodent models	79
	Conclusions	80
Chapter 5	Current initiatives in preclinical drug safety	84
	Summary	84
	Introduction	85
	The Predictive Safety Testing Consortium	86
	The International Life Sciences – Health and Environmental Sciences Institute	88

The InnoMed PredTox project	89
The Innovative Medicines Initiative	92
Additional consortia	93
The Chemical Effects in Biological Systems Database	93
The Japanese Toxicogenomics Project	93
Liver Toxicity Biomarker Study	94
Consortium for Metabonomic Toxicology	94
Other European funded initiatives	95
ACuteTox	95
Reprotec	96
Predictomics	96
CarcinoGenomics	97
Conclusions	97

Chapter 6 Strategies to improve safety evaluation in early clinical development 100

Summary	100
Introduction	101
Exploratory clinical trials	102
Other applications of AMS	106
Industry uptake	108
Regulatory status	108
The future for AMS-based studies	109
Technologies	109
Linking pharmacology data to microdose studies	109
Improving safety evaluation in Phase 1	110
Biomarkers in Phase 1 clinical trials	110
Pharmacogenomics and rare, idiosyncratic adverse events	115
Pharmacometrics – modeling and simulation to improve Phase 1 safety	116
Optimizing early clinical trial design	119
QT in Phase 1	121
The Thorough QT Study	121
Timing of the TQT study	124
Intensive QT studies in early Phase 1	124
Costs and decision making	125
Conclusions	125

Chapter 7 Challenges and cost saving opportunities 128

Summary	128
Introduction	129
Implementation of new technologies	129
New technologies, new risks	132
Qualifying biomarkers	133
Translational medicine	135
‘Fail early, fail often’	136
Conclusions	141

Chapter 8 Appendix 142

Primary research methodology	142
Acknowledgments	143
Index	144
Glossary	145
Glossary	145
Bibliography	148
Endnotes	153

List of Figures

Figure 1.1:	Pharma industry productivity decline (1995-2007)	19
Figure 1.2:	Reasons for drug attrition	24
Figure 1.3:	The place of innovative safety evaluation strategies in drug discovery and development	25
Figure 1.4:	Serious adverse events: research priorities	26
Figure 2.5:	In silico methods contribute to the earliest stages of drug discovery	33
Figure 2.6:	The Safety Intelligence Program from BioWisdom	39
Figure 2.7:	Examples of assertions in the Safety Intelligence Program from BioWisdom	40
Figure 3.8:	Novel in vitro methods and their use in drug discovery and development	50
Figure 3.9:	A typical toxicogenomics workflow in the pharma industry	52
Figure 4.10:	Novel in vivo methods and their use in drug discovery and development	70
Figure 4.11:	Whole body microPET images through a rat showing 18F-FDG distribution	75
Figure 5.12:	Study design and investigations used in the InnoMed PredTox project	90
Figure 6.13:	The ‘learn and confirm’ model of drug development	101
Figure 6.14:	The place of innovative technologies in early clinical safety assessment	102

Figure 6.15:	Comparison of midazolam pharmacokinetics at microdose and therapeutic dose levels in the CREAM study	105
Figure 6.16:	Proposed decision tree for integration of pharmacogenetic studies in early drug development	115
Figure 6.17:	Information utilized in model-based drug development	118
Figure 6.18:	Key attributes of a thorough QT study	123
Figure 7.19:	Success rate improvements from increasing investment in technologies for early safety prediction	139

List of Tables

Table 1.1:	Failure rates at each stage of clinical drug development	20
Table 1.2:	Drugs withdrawn from the market in the US between 1998 and April 2008	21
Table 3.3:	Examples of companies providing platforms for toxicogenomics	53
Table 3.4:	Examples of companies offering integrated software suites for the analysis of toxicogenomic data	55
Table 3.5:	Examples of contract laboratories offering HCA cytotoxicity screening	59
Table 3.6:	Examples of companies offering stem cells for toxicity testing	63
Table 4.7:	Advantages and disadvantages of zebrafish for toxicity screening	71
Table 4.8:	Companies offering zebrafish toxicity screening products and services	72
Table 4.9:	Advantages of molecular imaging of whole animals for preclinical studies	76
Table 4.10:	Manufacturers of molecular imaging equipment and probes	77
Table 4.11:	Companies developing transgenic models for ADMET testing	79
Table 5.12:	Biomarker candidates identified by the InnoMed PredTox project	91
Table 6.13:	Companies offering AMS services	103
Table 6.14:	Advantages and disadvantages of AMS-based microdosing studies	104
Table 6.15:	Advantages and disadvantages of using AMS for mass balance and absolute bioavailability studies	107
Table 6.16:	Core list of validated genomic biomarkers involved in ADME	112
Table 6.17:	Examples of valid genomic biomarkers in drug labels	113
Table 6.18:	Pharmacometric consultancies	119
Table 7.19:	Definitions and examples of safety biomarkers with different levels of qualification	134
Table 7.20:	Success rate improvements from increasing investment in technologies for early safety prediction	137
Table 7.21:	Success rate improvements from increasing investment in technologies for early safety prediction	140